| Title |
Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study
|
|---|---|
| Published in |
European Journal of Clinical Pharmacology, April 2012
|
| DOI | 10.1007/s00228-012-1283-9 |
| Pubmed ID | |
| Authors |
Jean-Pascal Fournier, Agnès Sommet, Robert Bourrel, Stéphane Oustric, Atul Pathak, Maryse Lapeyre-Mestre, Jean-Louis Montastruc |
| Abstract |
Non-steroidal anti-inflammatory drugs (NSAIDs) are known to antagonize the effects of antihypertensive drugs, and these associations can lead to an increase in arterial blood pressure. However, the impact of NSAIDs on hypertension treatment management in large-scale populations remains poorly evaluated. We examined whether the introduction of NSAID into the treatment regimen would induce an intensification of hypertension treatment (defined as the introduction of a new antihypertensive drug). |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 2 | 67% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| France | 1 | <1% |
| Unknown | 100 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 15 | 15% |
| Researcher | 11 | 11% |
| Student > Master | 9 | 9% |
| Student > Ph. D. Student | 7 | 7% |
| Student > Postgraduate | 6 | 6% |
| Other | 18 | 18% |
| Unknown | 36 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 11% |
| Biochemistry, Genetics and Molecular Biology | 4 | 4% |
| Business, Management and Accounting | 4 | 4% |
| Agricultural and Biological Sciences | 3 | 3% |
| Other | 9 | 9% |
| Unknown | 38 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2022.
All research outputs
#2,768,697
of 26,017,215 outputs
Outputs from European Journal of Clinical Pharmacology
#205
of 2,829 outputs
Outputs of similar age
#16,756
of 177,562 outputs
Outputs of similar age from European Journal of Clinical Pharmacology
#3
of 24 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,829 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.5. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 177,562 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.